Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allocetra in Knee Osteoarthritis
NCT06233474Phase 2Completed
- Sponsor
- Enlivex Therapeutics
- Start
- Jan 2024
- Primary completion
- Mar 2026
- Modality
- Cell Therapies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of Allocetra in knee osteoarthritis (OA) (3 arms), sponsored by Enlivex Therapeutics. Primary endpoint: Treatment-emergent adverse events and Serious adverse events at 7 months. Started Jan 2024; status: completed.
02
Drugs
Allocetra
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06233474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06233474.